<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02265549</url>
  </required_header>
  <id_info>
    <org_study_id>Radiomics SRT 09-2014</org_study_id>
    <nct_id>NCT02265549</nct_id>
  </id_info>
  <brief_title>Radiomics for Prediction of Long Term Survival and Local Failure After Stereotactic Radiotherapy for Brain Metastases</brief_title>
  <official_title>Value of Radiomics for the Prediction of Long Term Survival and Local Failure After Stereotactic Radiotherapy (SRT) for Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht Radiation Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht Radiation Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Published prognostic scores have limitations in prediction of long term survival after
      stereotactic radiotherapy for brain metastases. Moreover, no validated tools are available
      for prediction of local failure. The value of radiomics is evaluated in this perspective.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sensitivity is low for prediction of long term survival of currently available prognostic
      scores for brain metastases. First the current clinical models will be optimized with a new
      prognostic model and nomogram. Radiomics is a tool to analyze tumor characteristics based on
      CT and MR images. These tumor characteristics may reflect tumor biology and outcome.
      Therefore it is investigated if radiomics improves prediction of long term survival after
      stereotactic radiotherapy for brain metastases. Moreover, the predictive value of radiomics
      for local failure is investigated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2014</start_date>
  <completion_date type="Actual">September 4, 2014</completion_date>
  <primary_completion_date type="Actual">September 4, 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitive value of 12 months survival after stereotactic radiotherapy for brain metastases with radiomics</measure>
    <time_frame>1 year</time_frame>
    <description>Sensitivity of 12 months survival after stereotactic radiotherapy for brain metastases with radiomics. Radiomics is a tool to analyze tumor characteristics based on CT and MR images.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sensitive value of 12 months local failure after stereotactic radiotherapy for brain metastases with radiomics</measure>
    <time_frame>1 year</time_frame>
    <description>Sensitivity of 12 months local failure after stereotactic radiotherapy for brain metastases with radiomics. Radiomics is a tool to analyze tumor characteristics based on CT and MR images.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Specificity of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics.</measure>
    <time_frame>1 year</time_frame>
    <description>Specificity of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive predictive value of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics.</measure>
    <time_frame>1 year</time_frame>
    <description>Positive predictive value of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative predictive value of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics.</measure>
    <time_frame>1 year</time_frame>
    <description>Negative predictive value of 12 months survival and local failure after stereotactic radiotherapy for brain metastases with radiomics.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Area under the curve of published prognostic scores</measure>
    <time_frame>1 year</time_frame>
    <description>Area under the curve published prognostic scores</description>
  </other_outcome>
  <other_outcome>
    <measure>Mismatch rate of published prognostic scores</measure>
    <time_frame>1 year</time_frame>
    <description>Mismatch rate of published prognostic scores</description>
  </other_outcome>
  <enrollment type="Actual">155</enrollment>
  <condition>Metastases, Neoplasm</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with 1 upto 4 brain metastases treated with SRT
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cerebral metastasized patients

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Maastro Clinic</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 ET</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Zindler JD, Rodrigues G, Haasbeek CJ, De Haan PF, Meijer OW, Slotman BJ, Lagerwaard FJ. The clinical utility of prognostic scoring systems in patients with brain metastases treated with radiosurgery. Radiother Oncol. 2013 Mar;106(3):370-4. doi: 10.1016/j.radonc.2013.01.015. Epub 2013 Mar 20.</citation>
    <PMID>23522151</PMID>
  </results_reference>
  <results_reference>
    <citation>Rodrigues G, Zindler J, Warner A, Lagerwaard F. Recursive partitioning analysis for the prediction of stereotactic radiosurgery brain metastases lesion control. Oncologist. 2013;18(3):330-5. doi: 10.1634/theoncologist.2012-0316. Epub 2013 Feb 19.</citation>
    <PMID>23429647</PMID>
  </results_reference>
  <results_reference>
    <citation>Aerts HJ, Velazquez ER, Leijenaar RT, Parmar C, Grossmann P, Carvalho S, Bussink J, Monshouwer R, Haibe-Kains B, Rietveld D, Hoebers F, Rietbergen MM, Leemans CR, Dekker A, Quackenbush J, Gillies RJ, Lambin P. Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014 Jun 3;5:4006. doi: 10.1038/ncomms5006. Erratum in: Nat Commun. 2014;5:4644. Cavalho, Sara [corrected to Carvalho, Sara].</citation>
    <PMID>24892406</PMID>
  </results_reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2014</study_first_submitted>
  <study_first_submitted_qc>October 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2014</study_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastases,</keyword>
  <keyword>Neoplasm</keyword>
  <keyword>Cerebral</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Neoplasms, Second Primary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

